Loading clinical trials...

Investigating the Impact of Duration and Amount of Light on the Circadian System Response - Aim 3 | Clinical Trials | Clareo Health

COMPLETEDNA

Investigating the Impact of Duration and Amount of Light on the Circadian System Response - Aim 3

Methodology Issues in a Tailored Light Treatment for Persons With Dementia - Aim 3

NCT06595030•Icahn School of Medicine at Mount Sinai

View on ClinicalTrials.gov

Summary

Investigate the long-term impact of amount and duration of Tailored Lighting Intervention (TLI) obtained from Aims 1 and 2 on sleep, cognition, circadian marker, mood, and behavior in AD/ADRD patients. For this single-arm, randomized, placebo-controlled study, the researchers plan to recruit 100 participants who will experience either the active TLI or the placebo for 6 months.

Eligibility

Age

55 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Diagnosis of Alzheimer's disease or related dementia with a Montreal Cognitive Assessment score \<25
•Sleep disturbance with a Pittsburgh Sleep Quality Index score ≥5

Exclusion Criteria

•Extensive brain vascular disease, traumatic brain injury, multiple sclerosis, Parkinson's Disease
•Obstructing cataracts
•Severe macular degeneration
•Use of sleep medication
•Use of oral melatonin
•untreated moderate to severe sleep apnea
•Severe restless leg syndrome - Blindness

Locations (2)

Icahn School of Medicine at Mount Sinai

Menands, New York, United States

Icahn School of Medicine at Mount Sinai

New York, New York, United States

Key Dates

Start Date

December 3, 2024

Primary Completion Date

January 31, 2026

Completion Date

January 31, 2026

Last Updated

February 17, 2026

Enrollment

101

ACTUAL participants

Conditions

Alzheimer's DiseaseMild Cognitive Impairment

Interventions

Active Lighting Intervention

DEVICE

Control Lighting Intervention

DEVICE

ACP-204 in Adults With Alzheimer's Disease Psychosis

NCT06159673

Alzheimer's Disease Psychosis

View study

RECRUITINGPHASE1/PHASE2

Sense4Safety Intervention

NCT07220668

Mild Cognitive Impairment

View study

RECRUITING

Lombard Cohort of Brain Health Services

NCT07457138

Subjective Cognitive Decline (SCD)

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 17, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Investigating the Impact of Duration and Amount of Light on the Circadian System Response - Aim 3

Inclusion Criteria

Exclusion Criteria

ACP-204 in Adults With Alzheimer's Disease Psychosis

Sense4Safety Intervention

Lombard Cohort of Brain Health Services

Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease

A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)

Validating the On-line Creyos Cognitive Assessment Platform in Older Adults With Major Depressive Disorder or Mild Cognitive Impairment